Biopharma Stocks Transformative Innovation for the Future of Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
EF Hutton Starts Citius Pharmaceuticals (CTXR) at Buy
July 15, 2024 9:35 AM EDTEF Hutton analyst Jason Kolbert initiates coverage on Citius Pharmaceuticals (NASDAQ: CTXR) with a Buy rating and a price target of $6.00.
The analyst comments "Low-Risk and High-Reward. Citius has two late-stage therapeutics, Mino-Lok (MLT) and LYMPHIR. Both products have demonstrated efficacy and safety and are in the final stages of the approval process.... More
